Skip to content

MAZE MAZE Enterprise value

Enterprise value at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
Septerna, Inc. logo
Septerna, Inc.SEPN
$1.03B+1,325%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$1.77B+1,855%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$1.25B+502%
Zymeworks logo
ZymeworksZYME
$1.63B+112%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.63B+45.1%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Calculated from MAZE’s reported figures.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's enterprise value?
MAZE (MAZE) reported enterprise value of $1.34B in Q1 2026.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.